In a year marked by persistent headwinds for the healthcare sector, Baxter International Inc. (NYSE:{{7951|BABAX) stock has recorded a new 52-week low, touching down at $29.14. According to InvestingPro data, technical indicators suggest the stock is currently in oversold territory, while the company maintains its impressive 54-year streak of consecutive dividend payments. This latest dip underscores a challenging period for the medical equipment and service provider, which has seen its shares tumble by 24.24% over the past year. Investors have been cautious as the company grapples with various pressures, including increased competition and pricing scrutiny in the healthcare industry. The 52-week low serves as a stark indicator of the market's current sentiment towards Baxter, as stakeholders weigh the company's strategic moves to navigate through an increasingly complex healthcare landscape. InvestingPro analysis indicates the stock is currently undervalued, with analyst price targets suggesting potential upside, though three analysts have recently revised their earnings expectations downward.Want deeper insights? Access the comprehensive Pro Research Report for Baxter, available exclusively on InvestingPro, covering all essential metrics and expert analysis.
In other recent news, Baxter International Inc. announced significant board changes alongside robust Q3 2024 earnings. The company reported a 4% increase in sales year-over-year, reaching $3.85 billion, and an adjusted earnings per share (EPS) of $0.80, exceeding their guidance. This growth was primarily driven by a 7% increase in the Medical (TASE:PMCN) Products & Therapies segment, largely due to demand for the Novum IQ platform. Baxter also announced the impending sale of their Kidney Care business to Carlyle, expected to close in late 2024 or early 2025.
Board changes include the resignation of Mr. Peter M. Wilver from the Board of Directors, effective December 31, 2024, and appointing Mr. Jeffrey A. Craig as the new chairperson of the Audit Committee. Despite operational challenges due to Hurricane Helene, Baxter anticipates a resumed production of IV solutions by late November. The company projects full-year 2024 sales growth at 1% to 2%, with an adjusted EPS of $2.90 to $2.94. Baxter's executive team remains optimistic about the company's future, aiming for 4% to 5% top-line growth and an adjusted operating margin of 16.5% in 2025 post-separation from the Kidney Care business. These are recent developments for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.